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A HERBAL REMEDY DERIVED FROM SUBSPECIES OF ROSA CANINA,
IMPROVES THE IMMUNE RESPONSE, WORKING CAPACITY AND
WELL-BEING OF DOGS? A PARALLEL, PLACEBO-CONTROLLED,
DOUBLE-BLIND, RANDOMIZED STUDY
K. Winther1, A. Ragone1, A.V. Hansen1, P. Hansen1, A. Kharazmi2
1Dept. of Clinical Biochemisty, Frederiksberg Hosp., Univ. of Copenhagen,
Frederiksberg, Denmark; 2Dept. of Microbiol., RigsHosp.et, Univ. of
Copenhagen, Copenhagen, Denmark
Purpose: LitoVet a standardised powder made from subspecies of rose-hip
(rosa-canina), produced by Hyben-Vital, Langeland, Denmark, has shown
anti-inﬂammatory properties and improves the ﬂexibility of joints and
well-being in humans with osteoarthritis as well as in racing horse. It
has also been demonstrated that the present powder improves the quality
of human cartilage cells. The present study aimed to test whether the
same powder might improve the immune response, working capacity and
well-being of dogs.
Methods: Eighty six Greyhound dogs represented by both sexes mean
age 4.25±1.75 years and weight 30.95±4.0 kg were randomly allocated to
either LitoVet or placebo treatment for a three-month period. The animals
were randomized in blocks of three with two dogs given LitoVet 10 gram
daily as a dry powder added to the food and one dog given the same
amount of placebo powder with a similar taste, odour and colour. Both
groups were then treated for a three-month period.
The anti-inﬂammatory capacity was estimated as chemotaxis of periph-
eral blood neutrophil leucocytes using a Boyden chamber and opsonized
zymosan as a trigger and by estimating the total leukocyte counts. Anti-
oxidative capacity was estimated by using chemiluminescence. Working
capacity, endurance, motivation for different activities including training,
litheness, speed, mood and quality of the fur was evaluated by the staff
training the dogs by using standardised questionnaires after 6 and 12
weeks, respectively. In addition speed was estimated as meter/second
in hounds during competition. LitoVet and placebo treated dogs were
compared using Mann-Whitney. A p value of 0.050 or less was regarded as
statistically signiﬁcant.
Results: In vitro studies on neutrophils indicated a dose-dependent
anti-inﬂammatory and anti-oxidative capacity of LitoVet (p<0.048). Anti-
inﬂammatory and anti-oxidative properties were also detected in vivo
when the dogs had been treated for twelve weeks with LitoVet (p<0.046
and p <0.010, respectively). The questionnaires developed a consistent
pattern. After 6 weeks treatment only litheness showed signiﬁcant im-
provement in favour of active treatment (p<0.017). After 12 weeks of
treatment a signiﬁcant change in favour of LitoVet treatment as com-
pared to placebo was seen in the following parameters: working capacity
p<0.021, endurance p< 0.047, motivation for different activities including
training p<0.014, litheness 0.002, speed p< 0.027, mood p< 0.026 and
quality of the fur p<0.045. The improvement observed in the question-
naires was supported by the estimation of speed in competing dogs. There
was no signiﬁcant change in appetite or weight.
Conclusions: The present data suggest that LitoVet exhibits anti-inﬂamma-
tory properties in dogs and works as a strong antioxidant. This can explain
why the actively treated group of dogs showed an improvement in so many
different activities as working capacity, litheness, speed and quality of the
fur.
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HEALTH STATUS OF PATIENTS WHO RECEIVED TAPENTADOL PROLONGED
RELEASE DURING AN OPEN-LABEL EXTENSION STUDY
B. Kuperwasser1, E. McCann1, I. Van Hove2, R. Lange3, T. Häufel4,
M. Etropolski1
1Johnson & Johnson Pharmaceutical Res. & Dev. (PRD), L.L.C., Raritan, NJ;
2Johnson & Johnson PRD, Div. of Janssen Pharmaceutica, N.V., Beerse, Belgium;
3Global Dev., Grünenthal GmbH, Aachen, Germany; 4Global Drug Safety,
Grünenthal GmbH, Aachen, Germany
Purpose: Health status was assessed using the EuroQol-5 Dimension (EQ-
5D) questionnaire in a 1-year open-label extension study of tapentadol
prolonged release for the management of moderate to severe chronic pain
(ClinicalTrials.gov Identiﬁer: NCT00487435).
Methods: Patients were eligible for enrollment in this study if they com-
pleted 1 of 4 phase 3 studies (2 studies that evaluated the eﬃcacy of
tapentadol prolonged release and oxycodone controlled release compared
with placebo in patients with osteoarthritis pain [NCT00421928] or low
back pain [NCT00449176], a crossover study that evaluated dose conversion
between tapentadol immediate release and tapentadol prolonged release
in patients with low back pain [NCT00594516], or a 1-year study that
evaluated the long-term safety of tapentadol prolonged release compared
with oxycodone controlled release in patients with osteoarthritis or low
back pain [NCT00361504]). Patients who completed either of the eﬃcacy
studies, the crossover study, or who received oxycodone controlled release
in the 1-year safety study were titrated to their optimal therapeutic dose
of tapentadol prolonged release (100-250 mg bid) during a titration period
of up to 4 weeks, and all patients continued on their optimal dose during
a maintenance period of up to 48 weeks. Patients who received tapentadol
prolonged release in the 1-year safety study continued on their optimal
dose determined during that study. Average pain intensity during the past
24 hours was recorded every 4 weeks during the maintenance phase; mean
pain intensity at endpoint was calculated using the last observation carried
forward for values missing after early discontinuation. The EQ-5D mea-
sures health status using 5 dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression [3 possible levels: no problems,
some problems, or extreme problems], as well as a health status index;
patients completed an EQ-5D questionnaire at the end of treatment as well
as at Months 1, 2, 3, 6, 9, and 12. Treatment-emergent adverse events
(TEAEs) were recorded throughout the study.
Results: Patients (N = 1154) reported mean pain intensity scores of 3.87
at baseline and 3.65 at endpoint. At endpoint, the percentages of patients
(regardless of prior treatment) who reported the most positive response
on each dimension were as follows: no problems with mobility, 43.9%; no
problems in self-care, 82.9%; no problems with performing usual activities,
40.6%; no pain or discomfort, 17.2%; and no anxiety or depression, 71.7%.
Mean (standard error) changes from baseline on each dimension were as
follows: mobility, -0.0 (0.01); self-care, -0.0 (0.01); usual activities, -0.0
(0.02); pain or discomfort, -0.1 (0.02); and anxiety or depression, -0.0
(0.01). The mean (SE) change from baseline in health status index was 0.0
(0.01). The most common (≥10%) TEAEs reported during the study were
headache (13.1%), nausea (11.8%), and constipation (11.1%).
Conclusions: The eﬃcacy of tapentadol prolonged release for the manage-
ment of moderate to severe chronic pain and improvements in health status
with tapentadol prolonged release treatment have been demonstrated and
reported previously in phase 3 studies. Treatment with tapentadol pro-
longed release (100-250 mg bid) for up to 1 year in this open-label
extension study maintained pain control and health status for patients with
moderate to severe osteoarthritis or low back pain. These results support
the long-term use of tapentadol prolonged release for the management of
moderate to severe chronic pain.
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SCREENING, RECRUITMENT AND BASELINE CHARACTERISTICS OF THE
LONG-TERM EVALUATION OF GLUCOSAMINE SULPHATE (LEGS) STUDY
PARTICIPANTS
M. Fransen1, M. Agaliotis1, L. Nairn1, M. Votrubec1, L. Bridgett1,
M. Woodward2
1Univ. of Sydney, Lidcombe, Australia; 2The George Inst. for Intl. Hlth., Sydney,
Australia
Purpose: Clinical trials evaluating potential ’disease-modifying’ agents for
osteoarthritis are required to demonstrate both symptomatic and structural
beneﬁt. Ideally, to reduce ceiling or ﬂoor effects, study participants are
required to have at least moderate pain, yet retain suﬃcient tibiofemoral
joint space to allow the measurement of narrowing over time. To describe
study recruitment procedures and baseline demographics of people with
symptomatic knee osteoarthritis participating in the Long-term Evaluation
of Glucosamine Sulphate (LEGS) study (NCT00513422).
Methods: The LEGS study is a 2×2 factorial design randomised placebo-
controlled clinical trial allocating participants to glucosamine sulphate
(1500mg) and chondroitin sulphate (800mg) or matching placebo for two
years. Participants are required to attend annual clinic assessments (includ-
ing radiographs, knee MRI) and complete a bimonthly 7-day Participant
Diary collecting prospective data on pain, physical activity, analgesia and
work disability. Participants were recruited by small advertisements in
local and national newspapers or directly from general practice. The LEGS
study utilized a three stage screening process:
1. Telephone screening,
